[News Release] VLP Therapeutics Japan reports safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base [iScience][News Release] VLP Therapeutics Japan reports safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base [iScience]
[News Release] VLP Therapeutics Japan reports safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base [iScience]
VLP Therapeutics Japan, Inc. (VLPT Japan) researchers and their colleagues at the National Institutes of Biomedical Innovation, Health and Nutrition
[Preprint] Alphavirus replicon particle expressing IL-12 reprograms tumor-associated macrophages and neutrophils and induces anti-tumor immunity
VLP Therapeutics, Inc. (VLPT) researchers and their colleagues at the Stanford University School of Medicine posted on August 11 a
[Preprint] Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine
VLP Therapeutics, Inc. (VLPT) researchers and their colleagues at the Boston University Chobanian & Avedisian School of Medicine posted on
[Preprint] A Tetravalent Dengue Virus-like Particle Vaccine Induces High levels of Neutralizing Antibodies and Inhibits Dengue Replication in Non-Human Primates[Preprint] A Tetravalent Dengue Virus-like Particle Vaccine Induces High levels of Neutralizing Antibodies and Inhibits Dengue Replication in Non-Human Primates
[Preprint] A Tetravalent Dengue Virus-like Particle Vaccine Induces High levels of Neutralizing Antibodies and Inhibits Dengue Replication in Non-Human Primates
VLP Therapeutics, Inc. (VLPT) researchers and their colleagues at Nagasaki University and the National Institute of Infectious Diseases in Japan
- [Preprint] Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine, in healthy individuals
[Preprint] Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine, in healthy individuals
[Preprint] Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine, in healthy individuals
Wataru Akahata of VLP Therapeutics Japan and colleagues posted on September 6 a preprint* "Safety and immunogenicity of VLPCOV-02, a